Kenya’s private medical insurance market has reached a turning point. For four years, claims data from across the insured market has been building a picture that the industry can no longer ignore. Insurers are paying out more than they are collecting.  

Costs are rising far faster than inflation. Hospitals are charging vastly different prices for the same procedures, and patients have no way of knowing. The system is under serious strain, and a new industry report lays out exactly how deep the cracks run. 

According to the 2026 Kenya Medical Industry Analytics report, which consolidates fragmented insurer data into a coherent national picture for the first time, the medical-only claims ratio for 2025 sits at 101.8 per cent. This means insurers are paying out more in claims than they are collecting in premiums. The broader industry loss ratio, covering all insurance classes combined, holds at a healthier 77 per cent, but the medical line is pulling the entire sector down. 

Total insured claim amounts rose 54 per cent between 2022 and 2025, climbing steadily from Ksh29.7 billion, through roughly Ksh35 billion in 2023 and Ksh43 billion in 2024, to Ksh45.7 billion in 2025. In that final year, the ecosystem recorded 4.57 million claim visits across 1.39 million unique patients, up 6.9 per cent on 2024, at an average cost of Ksh33,000 per visit. 

Outpatient care absorbs 55 cents of every shilling claimed, a share that has barely shifted since 2022. Inpatient sits at 29 per cent, with dental and optical together accounting for around 12 per cent and maternity at 4 per cent. What is not stable is the cost trajectory. Underlying medical costs are rising at an average compound annual growth rate of 11 per cent, seven percentage points above Kenya’s general inflation rate of 4 per cent in 2025, and broadly in line with the 10.3 per cent global medical inflation projected for 2026 by Willis Towers Watson. Cumulatively, the average insured medical claim costs more than 50 per cent above what it did four years ago. 

The older, the costlier the medical bills 

Corporate schemes account for 97 per cent of all insured members; retail cover represents just 3 per cent. Children make up 45 per cent of the member mix, with principals at 39 per cent and spouses at 16 per cent. Female members account for 52 per cent of the total. The financial services sector dominates at 29 per cent of total membership. This is almost entirely a workforce-benefit product, which means employers, rather than individuals, hold most of the purchasing power, and most of the responsibility for what comes next. 

One of the report’s most consequential findings concerns how corporate medical schemes price their members, or more accurately, how they fail to do so. The cost curve by age is steep and entirely predictable. 

An inpatient visit for a patient aged 60 or above costs Ksh222,000 on average, while the same visit for a child aged 0 to 5 costs Ksh118,000. That is nearly a twofold difference, and the curve rises steeply and predictably across every age band in between. Outpatient care follows the same pattern: the oldest members cost roughly Ksh9,988 per visit against Ksh5,661 for the youngest. Frequency compounds this further. Patients over 60 average seven outpatient visits per year, compared to just three for those aged 11 to 18. 

Yet most corporate schemes in Kenya charge every member the same flat premium, regardless of age. A 28-year-old employee subsidises their 58-year-old colleague, invisibly and without any actuarial rationale. As the workforce ages and adverse selection tightens, with older, higher-cost employees opting into cover while younger, healthier ones opt out, flat pricing becomes increasingly untenable. This is a slow-motion market failure, and the data suggests it is already well underway. 

The hospital concentration 

Ten facilities account for half of all insured claims in Kenya. The cost spread across the top inpatient providers is considerable, and points to a total absence of a public price discovery mechanism.

Aga Khan Parklands charges more than 2.6 times what Mater Hospital does for broadly comparable inpatient services. Gertrude’s Children’s Hospital has posted the highest three-year outpatient cost growth among the top ten at 17 per cent. Smaller outpatient providers, meanwhile, cost on average 24 per cent less than the dominant ten, yet there is no public mechanism allowing patients to compare hospital pricing before treatment. Insurers hold internal tariff schedules but rarely disclose them, leaving patients largely blind to enormous cost differentials between facilities. 

The C-section problem 

Maternity accounts for only four per cent of total claims spent, but the data within that category raises questions that go far beyond insurance economics into clinical ethics and maternal health. 

Caesarean sections account for 54 per cent of all insured deliveries in Kenya, while the World Health Organization recommends a ceiling of 10 to 15 per cent. A caesarean costs an average of Ksh153,994, while a natural delivery costs Ksh81,706. The procedure is roughly twice as expensive, inflating the entire maternity claim line. 

Kenya’s disease burden 

Global surveys of medical insurance cost drivers consistently rank cancer, musculoskeletal disorders, and cardiovascular conditions at the top. Kenya’s private sector claims show that the insured population is overwhelmingly contending with acute, preventable conditions. 

Top 5 Outpatient Diagnoses by Spend (2025) 

1. Upper Respiratory Conditions: Ksh4.29 billion 
2. Gastrointestinal Conditions: Ksh2.38 billion 
3. Cardiovascular Conditions: Ksh1.69 billion 
4. General Medical Examinations: Ksh1.31 billion 
5. Reproductive System Conditions: Ksh0.97 billion 

Top 5 Non-Maternity Inpatient Diagnoses by Spend (2025) 

1. Gastrointestinal Conditions: Ksh1.29 billion 
2. Upper Respiratory Conditions: Ksh866 million 
3. Lower Respiratory Conditions: Ksh788 million 
4. Musculoskeletal Conditions: Ksh784 million 
5. Cardiovascular Conditions: Ksh620 million 

The dominance of respiratory and gastrointestinal illnesses suggests a failure in early primary care interventions. It also connects directly to broader environmental health concerns, including deteriorating urban air quality, inconsistent sanitation infrastructure, and water safety challenges. The volume of respiratory claims in particular places renewed scrutiny on environmental health policy in Nairobi and other major urban centres. 

The prescription landscape 

Medication accounts for 33 per cent of all outpatient visits by service type, making it the single largest driver of outpatient activity. Consultation accounts for a further 28 per cent, with laboratory at 16 per cent. When organised by therapeutic category, the prescription data reveals three distinct patterns. 

Antibiotics reliance 

Private outpatient care relies heavily on broad-spectrum antibiotics, a direct catalyst for Kenya’s escalating antimicrobial resistance burden. Augmentin (amoxicillin-clavulanate) leads all outpatient prescriptions by a wide margin, recorded in 103,388 visits, more than double the next most-prescribed drug in the entire system. Zinnat (cefuroxime) also appears in the top ten at 25,819 visits. Heavy reliance on this drug class is a well-documented driver of antimicrobial resistance, and Kenya’s AMR profile is already a recognised public health concern. 

Pain, fever, and inflammation medicine 

Cipladon, an opioid analgesic, ranks second overall at 65,411 visits. Below it sits three preparations of the same active ingredient: Paracetamol (49,847 visits), Panadol (46,155), and Parol (44,154), prescribed under different brand names and collectively forming the most widely used therapeutic group in the dataset. Brustan and Brufen together account for a further 76,014 visits. The brand fragmentation across this category suggests an absence of formulary discipline that a structured drug management programme could readily address. 

Antihistamines and muscle relaxants 

Zyrtec (cetirizine) appears at 42,897 visits, consistent with the upper respiratory burden that dominates outpatient diagnoses. Myospas, a muscle relaxant, rounds out the top ten at 24,952 visits, reflecting the musculoskeletal inpatient diagnosis load seen elsewhere in the data. 

On the diagnostic side, routine metabolic profiles tracking liver function, kidney function, and cholesterol panels lead outpatient laboratory spend. For inpatient, procalcitonin, a bacterial-infection biomarker, tops laboratory spend by a wide margin, consistent with the respiratory and gastrointestinal admission volumes. Brain MRI scans dominate inpatient radiology at approximately Ksh58,500 per visit on average; outpatient radiology is led by abdominal and pelvic ultrasound. 

The diagnosis data gap 

Ten per cent of all medical claims submitted carry no diagnosis code at all. Of the remaining 90 per cent that do include clinical coding, 79 per cent still rely on the outdated ICD-10 standard, while a mere 1 per cent use the current ICD-11 framework. With Ksh45.7 billion in total claims for 2025, the unclassified share represents approximately Ksh8.7 billion paid out annually on records that cannot be clinically categorised, used for risk stratification, or audited for fraud, waste, or over-utilisation. 

The report outlines six structural interventions: joint tariff negotiations across insurers to cap hospital pricing; age-based premium loadings to align pricing with actual risk; drug formularies and case management to contain outpatient spend; clinical engagement on caesarean section rates with tiered pricing on elective procedures; standardised cost-per-life-covered metrics for future tracking; and mandatory ICD coding compliance from providers as a non-negotiable condition for claim payouts. 

Sources: Kenya Medical Industry Analytics, 2026/AKI/ZEP-RE/Smart Access/Kenya Healthcare Federation. 

Data analytics & visualisation: Stanley Njihia   

Text: YvonneKawira